Non-Hodgkin Lymphoma
FDA Grants Approval to Durvalumab in MIBC
This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.
Read More
Exploring Innovations in Lymphoma Treatment With Russler-Germain
David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.
Listen
Reviewing RCC Treatment Choices After Progression With IO/TKI
During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
FDA Grants Azer-Cel Fast Track Status in DLBCL
Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell lymphoma.
Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC
A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.
